Type 2 diabetes trials in Brazil
35 of 39 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Where
- Aracaju - SE, Belo Horizonte, Blumenau, Brasília, Campinas, Curitiba, Fortaleza, Goiânia, Joinville, Maceió, Manaus, Natal, Porto Alegre, Ribeirão Preto, Rio de Janeiro, Santa Cecília, São José do Rio Preto, São Paulo
- Age
- 18 years and over
- People
- 11,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07064473 · EU 2025-521188-11-00 - Phase 3Not yet taking people in BrazilA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
- Where
- Campinas, Porto Alegre, São Paulo
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931547 · EU 2026-525471-13-00 - Phase 3Not yet taking people in BrazilAMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
- Where
- Campinas, Curitiba, Porto Alegre, São Paulo
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931573 · EU 2026-525472-26-00 - Phase 3Not yet taking people in BrazilA Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
- Where
- Campinas, Manaus, Porto Alegre, São Paulo
- Age
- 18 years and over
- People
- 1,060 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931599 · EU 2026-525474-20-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Where
- Goiânia, Natal, Porto Alegre, São José do Rio Preto, São Paulo
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Aracaju, Goiânia, Porto Alegre, Rio de Janeiro, São José do Rio Preto, São Paulo
- Age
- 18 years and over
- People
- 1,600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Where
- Belo Horizonte, Campinas, São Paulo
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07776509 · EU 2025-523295-23-00 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Where
- Brasília, Campinas, São José do Rio Preto, São Paulo
- Age
- 18 years and over
- People
- 954 worldwide
- Run by
- Pfizer
See details and how to joinNCT07595549 · EU 2026-525318-75-00 - Phase 3Taking peopleA Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Where
- Campinas, Goiânia, Passo Fundo, Porto Alegre, São Paulo
- Age
- 10 years to 17 years
- People
- 170 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07668336 · EU 2025-524811-35-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Where
- Curitiba, Fortaleza, São Paulo, Vitória, Votuporanga
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07392190 · EU 2025-523659-73-00 - Phase 3Taking peopleA Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Campinas, Curitiba, Porto Alegre, Rio de Janeiro, São Paulo
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07881458 · EU 2026-527230-31-00 - Phase 3Not yet taking people in BrazilA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
- Where
- Aracaju, Brasília, Campinas, Curitiba, Fortaleza, Porto Alegre, Recife, Rio de Janeiro, São Paulo, Vitória
- Age
- 45 years to 64 years
- People
- 3,000 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00 - Phase 3Taking peopleA Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Where
- Barretos, Brasília, Campinas, Curitiba, Fortaleza, Natal, Porto Alegre, Rio de Janeiro, São José dos Campos, São Paulo
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662109 · EU 2025-523941-81-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Where
- Belo Horizonte, Brasília, Campinas, Curitiba, Natal, Porto Alegre, Rio de Janeiro, São José dos Campos, São Paulo
- Age
- 18 years and over
- People
- 2,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00 - No phaseNot yet taking people in BrazilEvaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality
- Where
- Afogados da Ingazeira, Florianópolis
- Age
- 18 years and over
- People
- 45,000
- Run by
- epHealth
See details and how to joinNCT07846319 - Phase 3Taking peopleA Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Where
- Brasília, Campinas, Curitiba, Natal, Porto Alegre, São José dos Campos, São Paulo
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662213 · EU 2025-523933-24-00 - Phase 3Taking peopleA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- Where
- Bairro Rodolfo Teófilo, Fortaleza, Curitiba, Porto Alegre, Ribeirão Preto, São Paulo
- Age
- 10 years to 18 years
- People
- 80 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07282613 - Phase 3Taking peopleA Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
- Where
- Belém, Brasília, Campinas, Curitiba, Fortaleza, Porto Alegre, São José dos Campos, São Paulo
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07667803 - Phase 2Taking peopleTaurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes
- Where
- Porto Alegre
- Age
- 30 years to 80 years
- People
- 94
- Run by
- Hospital de Clinicas de Porto Alegre
See details and how to joinNCT04874012 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Where
- Brasília, Campinas, Fortaleza, Marília, Porto Alegre, Rio de Janeiro, São Paulo
- Age
- 18 years and over
- People
- 1,980 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07321886 · EU 2025-523657-34-00 - Phase 3Taking peopleAMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Where
- Aparecida de Goiânia, Belém, Bragança Paulista, Brasília, Campinas, Curitiba, Fortaleza, Goiânia, Manaus, Sao Jose Rio Preto, São Paulo, Uberlândia, Volta Redonda
- Age
- 45 years and over
- People
- 1,778 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07797335 - No phaseTaking peopleEffectiveness of the Brazilian Diabetes Prevention Program
- Where
- Goiânia, Viçosa
- Age
- 18 years and over
- People
- 1,305
- Run by
- Beneficência Portuguesa de São Paulo
See details and how to joinNCT06426277 - No phaseTaking peopleThe Impact of Geriatric Assessment on the Treatment Plan of Elderly Patients With T2DM
- Where
- Porto Alegre
- Age
- 60 years and over
- People
- 220
- Run by
- Hospital de Clinicas de Porto Alegre
See details and how to joinNCT06469437 - No phaseTaking peopleAutologous SVF Therapy for Type 2 Diabetes
- Where
- São Jose Do Rio Preto
- Age
- 18 years and over
- People
- 10
- Run by
- Kaiser Clinic and Hospital
See details and how to joinNCT07487467 - No phaseTaking peopleEffects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabetes Mellitus
- Where
- Bauru
- Age
- 18 years to 70 years
- People
- 32
- Run by
- University of Sao Paulo
See details and how to joinNCT07463859